Some promising pre-clinical results have already been reported for the pan-PAD inhibitor Cl-amidine, and its modified derivative BB-Cl-amidine, which were shown to reduce the severity of several inflammatory conditions in murine models for collagen-induced arthritis (CIA) [29], colitis [30] and lupus [31]. This evidence concerns the gene PADI4 and systemic lupus erythematosus.